Safety and Targeting of Anti-hk2 Antibody in mCRPC

Safety and Targeting of Anti-hk2 Antibody in mCRPC
Conditions:   Castration-Resistant Prostatic Cancer;   Metastatic Disease
Intervention:   Drug: 111In-DOTA-h11B6
Sponsors:   Tomopath Inc.;   Invicro;   Janssen Research & Development, LLC
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 5, 2019 / by / in
Comments